null

null

null

null

null

null

null

null

null

null

null

null

null

0.23x Total Debt / Equity (Conservative)

High sensitivity; Vireo carries significant debt typical of cannabis operators, and a 200bps rate rise would increase annual interest expense ~15-25%, pressuring already thin EBITDA margins

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) U.S.-Canada border (cannabis genetics/inputs); 2) State-level regulatory chokepoints where single-state licensing controls cultivation supply

Vireo operates almost exclusively in U.S. regulated cannabis markets; negligible international revenue, so sovereign currency devaluation exposure is effectively zero

Operations concentrated in U.S. state-licensed cannabis markets (MN, NY, MD, NM, PA); no material international revenue, so currency devaluation risk is not applicable

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

State-licensed cultivation facilities are non-substitutable inputs; single-state license dependencies create effective vendor/regulatory lock exceeding 30% of operational input in key markets

Cannabis retail/dispensary and wholesale; minimal cloud infrastructure dependency — a 30-day cloud termination would disrupt POS and compliance reporting but not core cultivation or dispensary operations

Vertically integrated cannabis producer-retailer; secondary revenue from wholesale biomass and white-label; cloud termination risk is operational disruption, not existential, given physical plant assets

Moderate API coupling risk via seed-to-sale tracking software (BioTrackTHC or Metrc); state-mandated systems create regulatory lock-in with no substitution permitted

Low Howey Test risk; revenue model is direct cannabis product sales (retail/wholesale), not investment contracts — no reasonable expectation of profits from others' efforts in the revenue stream

Very High

Moderate CCPA exposure from dispensary customer purchase data; GDPR exposure minimal given no EU operations; state cannabis data-sharing mandates create additional compliance overlay

Low federal antitrust risk; cannabis remains Schedule I federally, limiting interstate commerce arguments; state-level market share in MN/NY too small to trigger monopolization scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~80-85%); retail dispensary sales are point-of-sale transactions; limited recurring revenue from wholesale supply agreements (~15-20%)

Direct-to-consumer retail cannabis sales (primary); business-to-business wholesale flower and extract supply (secondary); no subscription or SaaS monetization

Price-taker in commoditizing state cannabis markets; limited premium pricing power as adult-use markets mature; stress-test shows 10-15% price compression feasible within 24 months of adult-use legalization

Weak (2/5); cannabis flower prices declining ~20-40% post-adult-use legalization in comparable markets; Vireo lacks dominant brand premium to offset commoditization

47.3% Gross Margin (Strong (40-60%))

Moderate free-rider leakage via illicit market substitution; legal cannabis customers can defect to untaxed black market if price differential exceeds ~20-30%

Revenue growth is largely headcount-linear; dispensary retail and cultivation require proportional staffing increases — doubling revenue likely requires ~70-80% headcount growth

High marginal cost; each new dispensary or cultivation expansion requires capital buildout plus proportional labor — limited operating leverage until multi-state scale achieved

Not applicable; Vireo operates company-owned licensed facilities, not a franchise model

At 10x scale, CAC likely declines modestly via brand awareness, but dispensary foot traffic remains geographically constrained; digital acquisition channels limited by cannabis advertising restrictions

No meaningful network effects; cannabis retail is a local, regulated, physical-goods business — additional customers do not improve product or experience for existing customers

-4.9% Return on Assets (Negative equity)

Moderate resilience (Tier 2); cannabis shows relative demand inelasticity, but discretionary premium SKUs vulnerable; illicit market gains share during consumer income compression

Adult recreational and medical cannabis consumers in licensed U.S. states; no single customer represents material concentration given retail dispensary model

Medical cannabis patients (state-registered) representing a more loyal, recurring sub-segment; wholesale B2B buyers (other dispensaries/processors) in select markets

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

10.5% CapEx / Revenue (Moderate-CapEx)

0001771706

VREOF